The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
OKYO Pharma Limited has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per ...
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results